TNFSF11 and osteoporosis: Denosumab, a monoclonal antibody that targets RANKL, has emerged as an important alternative in managing osteoporosis due to its potent ability to inhibit osteoclast-mediated bone resorption, offering a potential edge over traditional therapies.